Stock LLY ELI LILLY AND COMPANY
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Eli Lilly and Company

Equities

LLY

US5324571083

Pharmaceuticals

Market Closed - Nyse
Other stock markets
 04:00:02 2025-01-22 pm EST 		After market 05:43:32 pm
753.98 USD +1.57% Intraday chart for Eli Lilly and Company 752.76 -0.16%
09:56am Jefferies Adjusts Price Target on Eli Lilly to $1,020 From $996 MT
04:35am Robeco Global Consumer Trends down 0.37% in December - up in Novo Nordisk and Eli Lilly FW

Summary: Eli Lilly and Company

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • From a short-term investment perspective, the company presents a deteriorated fundamental situation

Highlights: Eli Lilly and Company

  • Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
  • The company's profit outlook over the next few years is a strong asset.
  • The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
  • The group's activity appears highly profitable thanks to its outperforming net margins.
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • Over the past twelve months, analysts' opinions have been strongly revised upwards.

Weaknesses: Eli Lilly and Company

  • The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 59.09 times its estimated earnings per share for the ongoing year.
  • Based on current prices, the company has particularly high valuation levels.
  • The company appears highly valued given the size of its balance sheet.
  • The valuation of the company is particularly high given the cash flows generated by its activity.
  • The company is not the most generous with respect to shareholders' compensation.

Ratings Chart: Eli Lilly and Company

surperformance-ratings-chart ELI-LILLY-AND-COMPANY
Source: Surperformance

ESG chart: Eli Lilly and Company

esg-ratings-chart ELI-LILLY-AND-COMPANY
Source: MSCI

Add to a list
Add to a list

0 selected

To use this feature you must be a member
Log inSign up
 Composite Fundamentals Composite Valuation Composite Momentum Capi. ($)
ELI LILLY AND COMPANY Stock Eli Lilly and Company
668B
JOHNSON & JOHNSON Stock Johnson & Johnson
357B
NOVO NORDISK A/S Stock Novo Nordisk A/S
356B
ABBVIE INC. Stock AbbVie Inc.
305B
MERCK & CO., INC. Stock Merck & Co., Inc.
243B
ROCHE HOLDING AG Stock Roche Holding AG
240B
ASTRAZENECA PLC Stock AstraZeneca PLC
211B
NOVARTIS AG Stock Novartis AG
197B
PFIZER, INC. Stock Pfizer, Inc.
151B
AMGEN INC. Stock Amgen Inc.
148B
Average 287.56B
Weighted average by Cap.
See all sector ratings
Investor Rating
Trading Rating
ESG MSCI
A

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

ESG

Environment
Social
Governance
Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. LLY Stock
  4. Ratings Eli Lilly and Company